查詢結果分析
相關文獻
- Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
- Durable Response to Lapatinib Plus Capecitabine in Trastuzumab--Resistant HER2 Over-expressing Metastatic Breast Cancer
- 賀癌平(Herceptin)/化學治療在轉移性乳癌之角色
- Epstein-Barr病毒與腫瘤抑制基因蛋白於主要唾液腺癌之表現
- Treatment Outcome in Women with Operable HER2-positive Breast Cancer: A Single Institutional Report
- Cardiotoxicity Associated with Trastuzumab Therapy in Taiwan: A Single Medical Center's 5-Year Experience
- Fever, Rash and Acute Inflammatory Polyarthritis in a Breast Cancer Patient after Trastuzumab Treatment: a Case Report
- Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
- Pertuzumab--晚期轉移性乳癌之治療新藥
- HER2免疫組織化學染色之檢體製備
頁籤選單縮合
題名 | Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer=Trastuzumab治療晚期第二型人類表皮生長因子受體表現陽性的唾液腺癌 |
---|---|
作者姓名(中文) | 楊鎰聰; 洪瑞隆; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 1:3 2014.12[民103.12] |
頁次 | 頁220-225 |
分類號 | 418.31 |
關鍵詞 | 賀癌平; 唾液腺癌; 第二型人類表皮生長因子受體; Trastuzumab; Salivary gland cancer; HER-2; |
語文 | 英文(English) |
中文摘要 | 唾液腺腺癌是頭頸部一種少見的腫瘤,具有復發及轉移的潛在特性,所以常被視為 高惡性度。由於臨床病例不多,目前並無標準的治療方式,但開刀切除是在疾病早期可 切除時的主要治療方式,且常在開刀後建議輔以放射線治療。全身性化學治療常保留給 晚期轉移性的病患上,且治療的成績往往不夠理想。隨著分子醫學的進步,唾液腺癌被 發現經常帶有多種分子的變異,可供治療的標的。我們在此提出一個案例報告,這是一 個 67 歲男性病患,診斷為第二型人類表皮生長因子受體表現陽性的轉移性唾液腺癌,在 使用含有 trastuzumab 的處方治療後,成功有效地控制腫瘤的生長。 |
英文摘要 | Salivary gland adenocarcinoma is a rare type of head and neck cancer and often has aggressive behavior with propensity to recur and metastasize. Currently, there are no standard treatment guidelines. Surgery is however, the mainstay of treatment in resectable disease and radiation is also considered for most patients after surgery. Systemic chemotherapy is reserved for metastatic cases, but its results are often disappointing. Recent development of molecular biology has shown that salivary gland caner has several molecular changes which may guide potential therapeutic targets. Here, we report a 67 year-old man diagnosed to have metastasized minor salivary gland adenocarcinoma with diffuse human epidermal growth factor receptor-2 (HER-2)-positive, by the immunohistochemical (IHC) stain. He was treated with a trastuzumabcontaining chemotherapeutic regimen with encouraging results. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。